Afferent Pharmaceuticals racks up $55 mln Series C
San Mateo, California-based Afferent Pharmaceuticals, a developer of drugs that treat neurogenic respiratory, urologic and pain disorders, has closed $55 million in Series C funding. Fidelity Management & Research Company led the round with participation from other investors that included Jennison Associates LLC (on behalf of certain clients), New Leaf Ventures, Partner Fund Management, Redmile Group, Tekla Healthcare Investors and Tekla Life Science Investors.
8 July 2015•5 mins read
